Navigation Links
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Date:10/6/2008

A>

About Vectura

Vectura Group plc is a product development company focused on the development of a range of inhaled therapies principally for the treatment of respiratory diseases. Vectura develops products to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis, a market which is forecast to double over the next ten years from $23 billion in 2007 to $46 billion by 2017. Vectura also develops products for non-respiratory diseases where optimised delivery via the lungs could provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies.

Vectura has eight products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to major pharmaceutical companies. The Company seeks to develop certain programmes further through development to optimise value through licensing at a later stage. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis where this complements Vectura's business strategy.

Vectura has development collaborations with several pharmaceutical companies including Boehringer Ingelheim, Novartis and Sandoz. The acquisition of Innovata in January 2007 brought established alliances with a number of additional companies, such as Baxter, GlaxoSmithKline (GSK), Merck Generics (part of Mylan Inc), UCB and Otsuka, as well as providing revenue streams, complementary products and critical mass. For further information, please visit Vectura's website at http://www.vectura.com

Forward-Looking Statements

This press release contains "forward-looking statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's or Vectura's actual results to differ mate
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
2. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
3. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
4. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
5. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Dignity Health St. Mary,s Medical Center ... With The Guidelines®-Stroke Silver-Plus Quality Achievement Award for ... American Heart Association/American Stroke Association for the treatment ... cause of death and a leading cause of ... , according to the American Heart Association/American ...
(Date:7/28/2014)... , July 28, 2014 Reportbuyer.com has ... Global Bone Densitometers Market 2014-2018 ... bone densitometry scan is a special type of X-ray ... bone. It is used primarily to detect osteopenia or ... and the risk of fractures is high. The purpose ...
(Date:7/28/2014)... Reportlinker.com announces that a new market ... Portugal Pharmaceuticals and Healthcare Report Q3 ... Includes 3 FREE quarterly updates ... last quarter has led us to revise our ... previously, BMI expects Portugal,s ...
Breaking Medicine Technology:Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4
... (Nasdaq: VICL ),today is presenting expanded clinical ... Vaxfectin(R) adjuvant may be broadly,applicable in DNA- and ... P. Rolland, Pharm.D., Ph.D., Vical,s,Senior Vice President of ... 8, at the World Vaccine Congress (Lyon, France ...
... Texas, Oct. 7 The Texas Cardiac Arrhythmia,Institute ... selected as one of,only a few sites in ... for a new device to treat persistent atrial ... specializing in heart,rhythm disorders, is a partnership between ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2
(Date:7/28/2014)... gluttons. We have long known that they monopolize large ... some tumor cells are also characterized by a series ... in an ordered set. Researchers are calling this behavior ... EPFL, Etienne Meylan,s research team was able to demonstrate ... mesenchymal behavior result from the same mechanism, at ...
(Date:7/28/2014)... July 29, 2014 The ... Situ Hybridization, Digital pathology & Workflow, Special ... Prostate Cancer, Non Small Cell Lung Cancer ... (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research ... Americas, Europe, BRIC, Japan & RoW) - ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A lush green ... playtime during the summer. However, the summer heat, lack of ... to become brown, weak and unhealthy. The Grounds Guys recommends ... Grow, Mow a lawn once a week and set the ... normal. This protects the grass roots from heat and allows ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
... have uncovered evidence that the abnormal editing of gene messages ... the development of lupus. Scientists hope the finding will lead ... therapy and possibly a new way to treat the disease. ... an enzyme that edits and modifies the messages of genes ...
... At the "World Aquaculture,2008", held on May ... from,the University of Strathclyde, Scotland, United Kingdom, was ... innovative statistical and,epidemiological research methods in sea-lice treatments ... an excellent example of commitment to,the advancement of ...
... money and time spent in intensive care units, researcher ... tubes coated with silver dramatically reduce infections from highly ... breathe through a tube placed through their trachea and ... developing what is called ventilator-associated pneumonia. , "Ventilator-associated pneumonia ...
... Murad, Inc. announced today,the appointment of Fernando Braga, ... for Latin America. In this position, Braga will,develop ... in key,areas, identify prospective partners and create new ... http://www.newscom.com/cgi-bin/prnh/20080519/LAM066 ), "Fernando joins the Murad family ...
... AUSTIN, TexasAging brings a sense of peace and calm, according ... The University of Texas at Austin. Starting at about age ... their younger counterparts. , Catherine Ross and John Mirowsky, professors ... Balance of Emotions in the May 19 issue of Social ...
... Anthem Members in six California, counties - Los Angeles, Alameda, Contra ... of Costs Associated with Medical ... Procedures, ... today the expansion of its industry-leading,transparency initiative into California. Now, approximately 1.8 ...
Cached Medicine News:Health News:Abnormal 'editing' of gene messages may be a cause of lupus 2Health News:Prof. Dr. George Gettinby Honored With Dieter Lutticken Award 2Health News:Prof. Dr. George Gettinby Honored With Dieter Lutticken Award 3Health News:Silver-Coated Endotracheal Tubes Cut Down on Infections 2Health News:Silver-Coated Endotracheal Tubes Cut Down on Infections 3Health News:Murad, Inc., Appoints Fernando Braga, Jr. as Director of International Business for Latin America 2Health News:With age comes a sense of peace and calm, population research center study shows 2Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 2Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 3
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: